US · CYPH · BIOTECHNOLOGY
Cypherpunk Technologies Inc. (CYPH) intrinsic value and stock valuation
$1.41as of 2026-11-21 · Mkt cap 41.53M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cypherpunk Technologies Inc. DCF and intrinsic value
InvestorsCraft values CYPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CYPH’s statements →
Cypherpunk Technologies Inc. Graham Number
Graham Number: $1.95d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- BriaCell Therapeutics Corp. (BCTX) $3.06
- Dare Bioscience, Inc. (DARE) $0.41
- Apollomics, Inc. (APLM) $15.54
- SeaStar Medical Holding Corporation (ICU) $0.94
- Curis, Inc. (CRIS) $0.43
- Citius Pharmaceuticals, Inc. (CTXR) $0.51
- Processa Pharmaceuticals, Inc. (PCSA) $1.56
- Aspire Biopharma Holdings, Inc. (ASBP) $7.13
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.5M |
| Operating income | -$-36.54M | -$-70.06M | -$-87.04M | -$-56.76M | -$-41.43M |
| Net income | $4.82M | -$-67.56M | -$-81.41M | -$-54.6M | -$-40.59M |
| EPSd | $68.2K | -$-1.8M | -$-3.98M | -$-4.82M | -$-4.73M |
| Operating cash flow | -$-43.9M | -$-60.3M | -$-43.75M | -$-49.04M | -$-35.16M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-43.9M | -$-60.3M | -$-43.75M | -$-49.04M | -$-35.16M |
| Total assets | $163.2M | $49.1M | $72.8M | $58.1M | $117.9M |
| Total debt | $40K | $270K | $260K | $520K | $470K |
| Net debt | -$-14M | -$-46.98M | -$-70.38M | -$-20.47M | -$-114.45M |
| Total equity | $153.5M | $35.1M | $60.1M | $54.6M | $107.9M |
| Cash and short-term investments | $14M | $47.3M | $70.6M | $43.8M | $114.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.5M |
| Cost of revenue | $0.00 | $0.00 | $430K | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | -$-430K | $0.00 | $1.5M |
| Research and development expenses | $25.7M | $57.2M | $73.2M | $45M | $32.2M |
| Selling, general and administrative expenses | $10.9M | $12.9M | $13.4M | $11.8M | $10.8M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $36.5M | $70.1M | $86.6M | $56.8M | $42.9M |
| Cost and expenses | $36.5M | $70.1M | $87M | $56.8M | $42.9M |
| Interest income | $920K | $3.13M | $4.03M | $930K | $10K |
| Interest expense | $20K | $0.00 | $0.00 | $50K | $40K |
| Depreciation and amortization | $0.00 | $10K | $430K | $20K | $30K |
| Ebitda | -$-36.54M | -$-70.05M | -$-80.99M | -$-54.38M | -$-40.54M |
| Operating income | -$-36.54M | -$-70.06M | -$-87.04M | -$-56.76M | -$-41.43M |
| Total other income/expenses, net | $46.6M | $3.09M | $5.63M | $2.31M | $810K |
| Income before tax | $10.1M | -$-66.97M | -$-81.41M | -$-54.45M | -$-40.61M |
| Income tax expense | $5.25M | $580K | $0.00 | $150K | -$-20K |
| Net income | $4.82M | -$-67.56M | -$-81.41M | -$-54.6M | -$-40.59M |
| Weighted average shares outstanding | $66.1M | $37.6M | $20.5M | $11.3M | $8.58M |
| Weighted average diluted shares outstanding | $70.7M | $37.6M | $20.5M | $11.3M | $8.58M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $14M | $47.3M | $70.6M | $43.8M | $114.9M |
| Net receivables | $148M | $700K | $770K | $1.36M | $1.19M |
| Inventory | $0.00 | $0.00 | $0.00 | $1.4M | $0.00 |
| Total current assets | $162.1M | $48M | $71.6M | $53.2M | $116.9M |
| Property, plant and equipment, net | $40K | $260K | $260K | $370K | $490K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $30K | $0.00 |
| Long-term investments | $150K | $0.00 | $0.00 | $150K | $0.00 |
| Total non-current assets | $1.1M | $1.08M | $1.23M | $4.88M | $1.04M |
| Total assets | $163.2M | $49.1M | $72.8M | $58.1M | $117.9M |
| Accounts payable | $1.98M | $4.74M | $6.46M | $1.54M | $4.19M |
| Short-term debt | $40K | $270K | $260K | $270K | $430K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $4.56M | $14.1M | $12.7M | $3.12M | $9.99M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $260K | $40K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.12M | $0.00 | $0.00 | $330K | $40K |
| Capital lease obligations | $40K | $270K | $260K | $520K | $470K |
| Total liabilities | $9.68M | $14.1M | $12.7M | $3.45M | $10M |
| Common stock | $80K | $40K | $30K | $140K | $90K |
| Retained earnings | -$-462.55M | -$-467.37M | -$-399.58M | -$-105.93M | -$-263.57M |
| Accumulated other comprehensive income (loss) | -$-100K | -$-120K | $110K | $0.00 | -$-270K |
| Total equity | $153.5M | $35.1M | $60.1M | $54.6M | $107.9M |
| Total investments | $150K | $0.00 | $0.00 | $22.9M | $0.00 |
| Total debt | $40K | $270K | $260K | $520K | $470K |
| Net debt | -$-14M | -$-46.98M | -$-70.38M | -$-20.47M | -$-114.45M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $4.82M | -$-67.56M | -$-81.41M | -$-54.6M | -$-40.59M |
| Depreciation and amortization | $0.00 | $10K | $10K | $20K | $30K |
| Stock-based compensation | $4.9M | $5.5M | $5.13M | $5.18M | $3.48M |
| Change in working capital | -$-8.56M | $1.29M | $2.51M | -$-650K | $1.01M |
| Accounts receivable | $150K | $0.00 | $1.3M | -$-1.01M | -$-1.16M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $1.16M |
| Accounts payable | -$-10.42M | $900K | $710K | $0.00 | $3.9M |
| Net cash provided by operating activities | -$-43.9M | -$-60.3M | -$-43.75M | -$-49.04M | -$-35.16M |
| Investments in property, plant and equipment | -$-97M | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $50.4M | $0.00 | $0.00 |
| Net cash used for investing activities | -$-97M | $0.00 | $49M | $0.00 | $0.00 |
| Common stock issued | $108.1M | $40M | $0.00 | $0.00 | $97.2M |
| Common stock repurchased | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $107.7M | $37.2M | -$-30K | -$-210K | $98M |
| Net change in cash | -$-33.21M | -$-23.39M | $5.14M | -$-49.42M | $62.8M |
| Cash at end of period | $14M | $47.3M | $70.6M | $65.5M | $114.9M |
| Operating cash flow | -$-43.9M | -$-60.3M | -$-43.75M | -$-49.04M | -$-35.16M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-43.9M | -$-60.3M | -$-43.75M | -$-49.04M | -$-35.16M |
Line items
Line items
Line items
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
- CEO
- Douglas E. Onsi
- Employees
- 6
- Beta
- 0.06
Explore
Frequently asked questions
What is the intrinsic value of Cypherpunk Technologies Inc. (CYPH)?
InvestorsCraft does not currently publish an intrinsic value for CYPH. How the IC value is calculated.
Is CYPH undervalued?
InvestorsCraft does not publish an undervaluation signal for CYPH at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.